Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2018
Source ID
10.1016/j.phrs.2018.09.007

Entities

People

  • Adrienne Arrieta
  • Alexandra Ahmet
  • Andrea L. Smith
  • Benjamin D. Schwartz
  • Craig M. McDonald
  • Diana Castro
  • Edward C Smith
  • Eric Hoffman
  • Jean K Mah
  • Jesse M. Damsker
  • John M. Mccall
  • John Van Den Anker
  • Kanneboyina Nagaraju
  • Laurel J. Mengle-gaw
  • Lauren P. Morgenroth
  • Laurie S. Conklin
  • Leanne M Ward
  • Mar Tulinius
  • Mark Jaros
  • Maya Shimony
  • Michaelyn R. Cornish
  • Michela Guglieri
  • Monique M. Ryan
  • Nancy Kuntz
  • Panteleimon D. Mavroudis
  • Paula R. Clemens
  • Phil Shale
  • Richard Finkel
  • Richard Webster
  • William J. Jusko
  • Yetrib Hathout
  • Yoram Nevo

Organizations

  • Muscular Dystrophy Association
  • National Institutes of Health
  • United States Department of Defense